Business Context and Reporting Period
This Form 8-K Current Report from Apyx Medical Corp covers events occurring on August 6, 2026, specifically the company's 2026 Annual Meeting of Stockholders. The filing details the outcomes of shareholder votes regarding board elections, auditor ratification, executive compensation, and equity incentive plans.
Key Financial Metrics
The filing text does not provide specific financial metrics such as revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance and shareholder voting results.
Material Changes and Voting Results
Shareholders approved four key proposals at the Annual Meeting:
- Proposal 1 (Election of Directors): Five directors were elected to serve until the 2027 Annual Meeting. Notably, two directors received significant "Against" votes:
- Stavros G. Vizirgianakis: 18,051,294 For vs. 4,083,005 Against.
- Minnie Baylor-Henry: 15,400,914 For vs. 6,650,608 Against.
- Wendy Levine: 15,395,258 For vs. 6,656,271 Against.
- Charles D. Goodwin and Lawrence J. Waldman received strong support with fewer than 800,000 "Against" votes each.
- Proposal 2 (Auditor Ratification): Stockholders ratified RSM US LLP as the independent registered public accounting firm for the year ending December 31, 2026, with 29,814,618 votes in favor and only 31,610 against.
- Proposal 3 (Executive Compensation): A non-binding advisory resolution supporting the compensation of named executive officers was approved with 21,458,554 votes in favor and 669,298 against.
- Proposal 4 (Share Incentive Plan): The 2026 Share Incentive Plan was approved with 16,186,776 votes in favor, 2,755,882 against, and 3,276,000 abstentions.
Guidance, Outlook, and Risks
The filing does not contain management commentary on future guidance, outlook, or specific risk factors. It references the definitive proxy statement filed on June 26, 2026, for detailed descriptions of the proposals and the full text of the 2026 Share Incentive Plan (Exhibit 10.1).
Investor Verification Checklist
- Review the Proxy Statement (Schedule 14A) filed on June 26, 2026, for detailed rationale behind the director elections and the 2026 Share Incentive Plan.
- Analyze the high volume of "Against" votes for directors Stavros G. Vizirgianakis, Minnie Baylor-Henry, and Wendy Levine to understand potential shareholder concerns regarding board composition.
- Examine Exhibit 10.1 to understand the terms, share limits, and vesting schedules of the newly approved 2026 Share Incentive Plan.
- Verify the total number of shares outstanding and the percentage of votes represented by the "Against" and "Abstained" tallies to assess the level of dissent.